MedTrace Logo

Mass Balance Study of FYU-981

NCT02901366 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-08-21

No results posted yet for this study

Summary

To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of FYU-981 after a single 1 mg oral dose of 14C-FYU-981 in healthy male subjects.

Conditions

  • Healthy Male Subjects

Interventions

DRUG

14C-FYU-981

14C-FYU-981, (Oral single dosing)

Sponsors & Collaborators

  • Mochida Pharmaceutical Company, Ltd.

    collaborator INDUSTRY

  • Fuji Yakuhin Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-01-31
Completion
2018-07-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02901366 on ClinicalTrials.gov